The two major mechanisms for the development of resistance during treatment are the occurrence of tumour cell clones which carry additional EGFR mutations or additional genetic alterations that can co-occur with EGFR-activating mutations (Lin and Bivona 2012). Here, EGFR is linked to neoplasm.